Use of natriuretic peptides in clinical decision-making for patients with non-ST-elevation acute coronary syndromes

American Heart Journal

Volumn 153, Issue 4, 2007, Pages 450-453

  de Lemos, James A ^a   Morrow, David A ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PLACEBO; TRANDOLAPRIL; VALSARTAN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INVASIVE PROCEDURE; MEDICAL INFORMATION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT;

ACUTE DISEASE; ANGINA, UNSTABLE; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SYNDROME;

EID: 33947314211     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.02.012     Document Type: Editorial

References (19)

1. de Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345 (2001) 1014-1021
2. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 41 (2003) 1264-1272
3. James S.K., Lindback J., Tilly J., et al. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. J Am Coll Cardiol 48 (2006) 1146-1154
4. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
5. Bazzino O., Fuselli J.J., Botto F., et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 25 (2004) 859-866
6. Galvani M., Ottani F., Oltrona L., et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 110 (2004) 128-134
7. James S.K., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108 (2003) 275-281
8. Morrow D.A., de Lemos J.A., Blazing M.A., et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 294 (2005) 2866-2871
9. Kragelund C., Gronning B., Kober L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
10. Richards M., Nicholls M.G., Espiner E.A., et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 47 (2006) 52-60
11. Windhausen F., Hirsch A., Sanders G., et al. N-terminal pro-B-type natriuretic peptide for additional risk stratification in patients with non ST elevation acute coronary syndromes and an elevated troponin T: an ICTUS substudy. Am Heart J (2007) [in press]
12. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical characteristics & utilization of biochemical markers in acute coronary syndromes. Clin Chem (2007) [in press]
13. Ndrepepa G., Braun S., Mehilli J., et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 95 (2005) 553-557
14. Sadanandan S., Cannon C.P., Chekuri K., et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 44 (2004) 564-568
15. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44 (2004) 1988-1995
16. Omland T., Sabatine M.S., Jablonski K.A., et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J Am Coll Cardiol (2007) [in press]
17. Jernberg T., Lindahl B., Siegbahn A., et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42 (2003) 1909-1916
18. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344 (2001) 1879-1887
19. The FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 354 (1999) 708-715